Previous Close | 0.9800 |
Open | 1.1000 |
Bid | 0.9200 |
Ask | 0.9700 |
Strike | 106.00 |
Expire Date | 2024-05-10 |
Day's Range | 0.8200 - 1.1000 |
Contract Range | N/A |
Volume | |
Open Interest | 160 |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.